Biotech start-up Invenra recently announced a partnership collaboration with Exelixis to develop multispecific antibodies as cancer therapies.
Their partnership agreement allows Exelixis to expand its current small molecule pipeline to create a biologics pipeline able to provide new anti-ancer therapies, says GlobalData, a leading data and analytics company.
The partnership combines the biological insight, clinical development, and commercialisation expertise of Exelixis with the innovative platforms and biologics expertise of Invera.
This will facilitate the identification and optimisation of lead candidates leading to the manufacture of multispecific therapies, which include immunotherapies.
Exelixis will be able to create an innovative pipeline past the commercially available compounds of cabozanitinib and cobimetinib.
Sharon Cartic, Managing Pharma Analyst at GlobalData, says: “The agreement terms allow both Exelixis and Invenra to utilise Invenra’s B-Body technology platform, which allows high throughput and functional screening in addition to in vitro and in vivo preclinical studies for lead antibodies.”
“Exelixis will then take on investigational new drug (IND)-enabling studies, manufacturing, and clinical development, and also regulatory approval and commercialisation in the future.”
The collaboration stipulates that Exelixis receives a worldwide license to one preclinical candidate, and that both Exelixis and Invenra have the intention to pursue up to six additional projects together.
Invenra will receive an upfront payment of $2 million and then a further $2 million at the start of each discovery project from Exelixis.
Invenra has the potential to receive up to $131.5 million through preclinical, clinical, and regulatory milestone payments for a single preclinical lead candidate in its first indication.
Reaching commercialisation will then allow Invenra to receive a global milestone payment of up to $325 million based on sales achieved. In addition, single tiered royalties will be received based on marketed drug sales.
Cartic adds: “Invenra has also had other partnership deals with companies such as Merck, the QIMR Berghofer Medical Research Institute, AgonOx, and Oxford BioTherapeutics, with many also involved in developing new cancer therapies.”
“Invenra also previously invested in its future of developing drugs by raising $2.9 million in venture financing in September 2017. Partnership collaborations between startup biotechs and pharma companies are a popular strategic deal for companies getting novel cancer drugs to market.”